Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

被引:15
作者
Alves, Katia [1 ]
Plested, Joyce S. [1 ]
Galbiati, Shirley [1 ]
Chau, Gordon [1 ]
Cloney-Clark, Shane [1 ]
Zhu, Mingzhu [1 ]
Kalkeri, Raj [1 ]
Patel, Nita [1 ]
Smith, Kathy [1 ]
Marcheschi, Alex [1 ]
Pfeiffer, Susan [1 ]
McFall, Heather [1 ]
Smith, Gale [1 ]
Glenn, Gregory M. [1 ]
Dubovsky, Filip [1 ]
Mallory, Raburn M. [1 ]
机构
[1] Novavax, Gaithersburg, MD 20878 USA
关键词
D O I
10.1056/NEJMc2215509
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fourth Dose of SARS-CoV-2 Adjuvanted Protein VaccineBoosters of adjuvanted NVX-CoV2373 protein vaccine led to increasing neutralizing titers of antibody specific for the ancestral strain and omicron variants. Whether the elicited antibodies protect against infection is unclear.
引用
收藏
页码:857 / 859
页数:3
相关论文
共 5 条
  • [1] Glenn GM., 2022, VACCINES RELATED BIO
  • [2] Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
    Huang, Yunda
    Borisov, Oleg
    Kee, Jia Jin
    Carpp, Lindsay N.
    Wrin, Terri
    Cai, Suqin
    Sarzotti-Kelsoe, Marcella
    McDanal, Charlene
    Eaton, Amanda
    Pajon, Rolando
    Hural, John
    Posavad, Christine M.
    Gill, Katherine
    Karuna, Shelly
    Corey, Lawrence
    McElrath, M. Juliana
    Gilbert, Peter B.
    Petropoulos, Christos J.
    Montefiori, David C.
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [3] Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
    Mallory, Raburn M.
    Formica, Neil
    Pfeiffer, Susan
    Wilkinson, Bethanie
    Marcheschi, Alex
    Albert, Gary
    McFall, Heather
    Robinson, Michelle
    Plested, Joyce S.
    Zhu, Mingzhu
    Cloney-Clark, Shane
    Zhou, Bin
    Chau, Gordon
    Robertson, Andreana
    Maciejewski, Sonia
    Hammond, Holly L.
    Baracco, Lauren
    Logue, James
    Frieman, Matthew B.
    Smith, Gale
    Patel, Nita
    Glenn, Gregory M.
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (11) : 1565 - 1576
  • [4] Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine
    Shinde, Vivek
    Fries, Louis
    Glenn, Gregory M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) : 2346 - 2348
  • [5] van der Straten K., 2022, MEDRXIV, DOI [10.1101/2022.01.03.21268582v1, DOI 10.1101/2022.01.03.21268582V1]